Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain

Nitric Oxide - Biology and Chemistry

Volumn 7, Issue 4, 2002, Pages 297-300

  Tarazi, Frank I ^a,b   Zhang, Kehong ^a,b   Baldessarini, Ross J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoradiography; Frontal cortex; Hippocampus; L Ng nitroarginine; Olanzapine; Quetiapine; Risperidone

Indexed keywords

NEUROLEPTIC AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEURONAL NITRIC OXIDE SYNTHASE; NOS1 PROTEIN, RAT; PIRENZEPINE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; BRAIN REGION; CONTROLLED STUDY; DENSITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ANALYSIS; FOREBRAIN; MALE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SYNTHESIS; ANIMAL; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; SPRAGUE DAWLEY RAT; TIME;

ANIMALIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BENZODIAZEPINES; BRAIN; DIBENZOTHIAZEPINES; INFUSIONS, INTRAVENOUS; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; TIME FACTORS; TRITIUM;

EID: 0036434494     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-8603(02)00126-X     Document Type: Article

References (25)

1. D.S. Bredt, S.H. Snyder, Nitric oxide, a novel second messenger, Cell 8 (1992) 3-11.
2. J. Garthwaite, C.L. Boulton, Nitric oxide signaling in the central nervous system, Annu. Rev. Physiol. 57 (1995) 683-706.
3. D.S. Bredt, P.M. Hwang, S.H. Snyder, Localization of nitric oxide synthase indicating a neural role for nitric oxide, Nature 347 (1990) 768-770.
4. g-nitroarginine binding in rat brain, Neuropharmacology 34 (1995) 63-73.
5. S. Akbarian, A. Vinuela, J.J. Kim, S.G. Potkin, W.E. Bunney, E.G. Jones, Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development, Arch. Gen. Psychiatry 50 (1993) 178-187.
6. C.N. Karson, W.S.T. GriQn, R.E. Mrak, M. Husain, T.M. Dawson, S.H. Snyder, N.C. Moore, W.Q. Sturner, Nitric oxide synthase (NOS) in schizophrenia: Increases in cerebellar vermis, Mol. Chem. Neuropathol. 27 (1996) 275-284.
7. I. Das, N.S. Khan, B.K. Puri, S.R. Hirsch, Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production, Neurosci. Lett. 215 (1996) 209-211.
8. I. Das, N.S. Khan, B.K. Puri, S.R. Sooranna, J. de Belleroche, S.R. Hirsch, Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain, Biochem. Biophys. Res. Commun. 212 (1995) 375-380.
9. M. Fratelli, R. Delgado, M. Zinetti, G. Galli, Y. Rolland, P. Ghezzi, Chlorpromazine inhibits nitric oxide-mediated increase in intracellular cGMP in a mouse teratocarcinoma cell line, Inflamm. Res. 44 (1995) 287-290.
10. J. Hu, J.H. Lee, E.E. El-Fakahany, Inhibition of neuronal nitric oxide synthase by antipsychotic drugs, Psychopharmacology 114 (1994) 161-166.
11. C.M. Pudiak, M.A. Bozarth, Nitric oxide synthesis inhibition attenuates haloperidol-induced supersensitivity, J. Psychiatry Neurosci. 22 (1997) 61-64.
12. E.A. Del Bel, F.S. Guimaraes, Sub-chronic inhibition of nitric oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice, Psychopharmacology 147 (2000) 356-361.
13. T. Abekawa, T. Ohinori, T. Koyama, Effect of NO synthase inhibition on behavioral changes induced by a single administration of methamphetamine, Brain. Res. 666 (1994) 147-150.
14. R.J. Baldessarini, F.I. Tarazi, Drugs and the treatment of psychiatric disorders: Antipsychotic and antimanic agents, in: J.G. Hardman, L.E. Limbird (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, 2001, pp. 485-520.
15. J. Arnt, T. Skarsfeldt, Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology 18 (1998) 63-101.
16. F.I. Tarazi, K. Zhang, R.J. Baldessarini, Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment, J. Pharmacol. Exp. Ther. 297 (2001) 711-717.
17. B.A. Ellenbroek, L.J. Lubbers, A.R. Cools, Activity of Seroquel (ICI-204,636) in animal models for atypical properties of antipsychotics, comparison with clozapine, Neuropsychopharmacology 15(1996) 406-416.
18. N.A. Moore, N.C. Tye, M.S. Axton, F.C. Risius, The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent, J. Pharmacol. Exp. Ther. 270 (1992) 713-721.
19. g-nitroarginine in rat brain, Br. J. Pharmacol. 109 (1993) 287-288.
20. A.R. West, M.P. Galloway, Nitric oxide and potassium chloride-facilitated striatal dopamine efflux in vivo: Role of calcium-dependent release mechanisms, Neurochem. Int. 33 (1998) 493-501.
21. F. Fujiyama, S. Masuko, Association of dopaminergic terminals and neurons releasing nitric oxide in the rat striatum: An electron microscopy study using NADPH-diaphorase histochemistry and tyrosine hydoxylase immunocytochemistry, Brain. Res. Bull. 40 (1996) 121-127.
22. P. Seeman, Brain dopamine receptors, Pharmacol. Rev. 32 (1980) 229-313.
23. D.R. Burt, I. Creese, S.H. Snyder, Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding, Science 196 (1977) 326-328.
24. Y.S. Lau, M.E. Gnegy, Chronic haloperidol treatment increased calcium-dependent phosphorylation in rat striatum, Life Sci. 30 (1982) 21-28.
25. F. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1982.